Cite

HARVARD Citation

    Forero, A. et al. (n.d.). Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record